AzTrials
AzTrials

ECMO Cannula InfectionECMO-CSI-DIAGNCT07893639

Diagnosis of ECMO Cannula Infection: Prospective Comparison of Sampling Methods

An observational study of ECMO Cannula Infection and Extracorporeal Membrane Oxygenation Complication, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Extracorporeal membrane oxygenation (ECMO) is increasingly used as rescue support in patients with refractory respiratory and/or circulatory failure. ECMO cannula site infection (ECMO-CSI) complicates approximately 10% of ECMO runs and is associated with septic shock, prolonged intensive care unit (ICU) stay and… Read more about this study

Who is it for?
Ages 18 years and older
How many people
500 participants
Where
1 siteFrance
Study dates
1 Nov 2026to Jan 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients managed in the medical intensive care unit of Pitié-Salpêtrière Hospital (Paris, France) on veno-venous or veno-arterial ECMO during the inclusion period.

Who may be able to join

  • Age >= 18 years
  • Patient admitted to the intensive care unit with veno-venous or veno-arterial ECMO

Who cannot join

  • Pregnant women
  • Persons deprived of liberty
  • Sample collection impossible for technical reasons
  • Patients on central ECMO

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site
  • Hôpital Pitié Salpêtrière, Service de médecine intensive et réanimation

    Paris

    Charles-Edouard LUYT, MD, PhD, +33 01 42 16 38 24, charles-edouard.luyt@aphp.fr

    Laure FLURIN, MD, PhD, +33 01 84 82 79 76, laure.flurin@aphp.fr

Other trials in France

About this study

Official title: Diagnosis of ECMO Cannula Infection: a Prospective Comparison of Sampling Methods

Extracorporeal membrane oxygenation (ECMO) is increasingly used as rescue support in patients with refractory respiratory and/or circulatory failure. ECMO cannula site infection (ECMO-CSI) complicates approximately 10% of ECMO runs and is associated with septic shock, prolonged intensive care unit (ICU) stay and increased mortality. To date, there is neither a standardized definition nor consensus diagnostic criteria for ECMO-CSI, and the optimal microbiological sampling strategy, as well as the diagnostic accuracy of the available methods, remains undetermined.

This single-center, prospective, non-interventional study aims to compare the diagnostic accuracy of three microbiological sampling methods (superficial swab of the cannula insertion site, needle aspiration along the cannula tract, and cannula tip culture) for the diagnosis of ECMO-CSI in adult patients receiving veno-venous or veno-arterial ECMO.

Read more

A superficial swab and a needle aspirate will be obtained at each cannulation site on the day ECMO-CSI is clinically suspected and on the day of decannulation. In addition, the tip of each cannula will be cultured at decannulation. The results of these index tests will be compared with a reference diagnosis of ECMO-CSI established by an adjudication committee of expert clinicians blinded to the index test results.

A total of 500 patients will be enrolled in order to obtain at least 50 patients with adjudicated ECMO-CSI.

Read the detailed description

BACKGROUND ECMO is a life-support technique widely used in refractory respiratory and/or circulatory failure. It is associated with infectious complications, notably cannula infections, whose incidence is estimated at about 10%. These infections are associated with an increased risk of septic shock and contribute to longer ICU stay and higher mortality. There is to date neither a standardized definition nor consensus diagnostic criteria, particularly regarding the nature and diagnostic performance of the microbiological samples to be collected. Superficial swabbing of the insertion site is simple and minimally invasive but frequently yields contaminated results or results reflecting colonizing flora. More invasive methods (needle aspiration, culture of the cannula tip at decannulation) may be more specific but are less commonly performed and have not been comparatively validated. A recent international Delphi consensus identified cannula aspiration and cannula swab as the two preferred microbiological methods. The lack of an established diagnostic algorithm leads to heterogeneous management, with potential consequences for antibiotic stewardship and patient outcomes.

DESIGN Single-center, prospective, non-interventional study conducted in the medical ICU of Pitié-Salpêtrière Hospital (AP-HP, Paris, France), which manages about 300 ECMO patients per year. All adult patients on veno-venous or veno-arterial ECMO are eligible. The patient (or trusted person, relative or legal representative) is informed and the patient is included unless an objection is expressed. Inclusion period: 24 months. Participation: duration of ICU stay (maximum 2 months). Total study duration: 26 months.

SAMPLING

  • Swab (performed for the research): a sterile single-use swab is applied to the cannula insertion orifice.
  • Needle aspiration (standard of care): 1 mL of sterile saline is injected along the cannula through a syringe and a plastic catheter, re-aspirated and transferred to a sterile container.
  • Cannula tip (standard of care): at decannulation, the distal 5 cm of the cannula is cut with a sterile blade and placed in a sterile container.

On the day the clinician in charge suspects a cannulation site infection, a swab and a needle aspiration are performed at each cannulation site. On the day of decannulation, a swab and a needle aspiration are performed at each cannulation site and the tip of each cannula is sent for culture.

MICROBIOLOGY Samples are cultured in the microbiology laboratory using the Brun-Buisson technique: suspension in 1 mL of sterile saline and vortexing for about 1 minute, then 100 microliters are plated on fresh blood agar, chocolate agar and Sabouraud agar, incubated for 48 hours to 10 days under aerobic and anaerobic conditions and read daily. In case of positive culture, identification is performed by mass spectrometry (MALDI-TOF). Each sample is recorded as culture positive or culture negative.

REFERENCE STANDARD The reference diagnosis of ECMO cannula infection is the clinical diagnosis established by an adjudication committee of three clinician experts, ruling retrospectively and blinded to the results of the index tests, on the basis of the available clinical, biological, microbiological and outcome data.

DATA Data are collected prospectively from the electronic medical record into a REDCap electronic case report form hosted by AP-HP. At each sampling: local appearance of the insertion site (photograph), general and hemodynamic status, biological inflammatory markers, nosocomial infection during the stay, antibiotic therapy within the previous 7 days, rectal colonization with a multidrug-resistant organism, positive blood culture within the previous 48 to 72 hours, duration of ECMO support.

STATISTICS The sample size was set to obtain at least 50 cases of cannula infection; with an expected incidence of 10%, 500 patients will be included. Sensitivity, specificity and predictive values of each sampling strategy are computed against the reference diagnosis. Paired comparisons use the McNemar test. Agreement between methods is assessed with the kappa coefficient. Exploratory logistic regression analyses will identify factors associated with microbiological positivity. Analyses are performed on complete cases; a failed sampling technique is considered negative.

Keywords
ECMO, Cannula infection, Cannulation site infection, Diagnostic performance, swab, Needle aspiration, Cannula tip culture, microbiological sampling

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07893639
Study groupRoleWhat they receive
Adult patients on ECMOAdult patients on veno-venous or veno-arterial ECMO in the ICU. Swab and needle aspiration of each cannulation site on the day of clinical suspicion of cannula infection and on the day of decannulation; culture of each cannula tip at decannulation.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnostic performance of each sampling strategy (superficial swab, needle aspiration, cannula tip culture) for the diagnosis of ECMO cannula infection

    Sensitivity, specificity, positive and negative predictive values of each sampling strategy, and its agreement with the reference diagnosis of cannula infection established by the adjudication committee.

    Measured: On the day of clinical suspicion of cannula infection and on the day of decannulation, up to ICU discharge (maximum 2 months)

Secondary outcomes (2)
  1. Factors associated with positivity of the microbiological samples

    Variables assessed at each sampling: weight (kg); height (meters), BMI (kg/m2), local appearance of the cannula insertion site on a photograph (purulence, inflammatory signs), fever (temperature (°C), systolic blood pressure (mmHg), diastolic blood pressure (mmHg), heart rate (bpm), noradrenaline (µg/kg/min), dobutamine (µg/kg/min)), biological criteria: hemoglobin (g/dL), white blood cell count (G/L), CRP (mg/L), PCT (ng/l), pH, bicarbonates (mmol/L), arterial lactate (mmol/L), nosocomial infection during the stay, antibiotic therapy within 7 days before sampling, rectal colonization with a multidrug-resistant organism, positive blood culture within 48 to 72 hours before sampling, positive culture of the ECMO cannula tip, duration of ECMO support.

    Measured: On the day of clinical suspicion of cannula infection and on the day of decannulation, up to ICU discharge (maximum 2 months)

  2. Agreement between the sampling methods

    Agreement on culture positivity and on microbiological identification between swab, needle aspiration and cannula tip culture (kappa coefficient).

    Measured: On the day of clinical suspicion of cannula infection and on the day of decannulation, up to ICU discharge (maximum 2 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Oct 2026
  2. Study start1 Nov 2026 (estimated)
  3. Primary completionJan 2029 (estimated)
  4. Study completionJan 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07893639
Sponsor's protocol ID
APHP260913
Acronym
ECMO-CSI-DIAG
Status last verified
Nov 2026
First submitted
19 Oct 2026
Last updated
6 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of ECMO Cannula Infection and Extracorporeal Membrane Oxygenation Complication, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Charles-Edouard LUYT (+33 01 42 16 38 24, charles-edouard.luyt@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnostic performance of each sampling strategy (superficial swab, needle aspiration, cannula tip culture) for the diagnosis of ECMO cannula infection (time frame: On the day of clinical suspicion of cannula infection and on the day of decannulation, up to ICU discharge (maximum 2 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in